Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

EARLY_PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective longitudinal study aims at evaluating the clinical efficacy of human amniotic fluid extract eye drops in the treatment of dry eye disease. 25 patients who are diagnosed with dry eye disease as defined by our criteria will be recruited from the cornea and dry eye clinic at Stein Eye Institute, UCLA. Pre-treatment baseline evaluations, 6 weeks, 12 weeks, and 24 weeks post treatment assessments will be performed by the principle investigator and co-investigator. All tests are considered non-invasive and are within the standard of practice in the evaluation for dry eye disease: (1) Ocular Surface Disease Index Questionnaire (OSDI); (2) Non-contact Tear Break-up Time (NITBUT); (3) Shirmer's test without anesthesia; (4) Ocular Surface Staining with Fluorescein and Lissamine green. Result of each test will be compared and analyzed to provide evidence of treatment efficacy. Treatment will be initiated for 12 weeks at a self-administered dose of one drop in both eyes two times per day. A follow-up of the study will be observed at the 24th week from the first day of treatment. All side effects and adverse events will be carefully observed and documented. Patients will be able to discontinue using the medication if they are not tolerating any side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amniotic Membrane Treatment for Hyposecretory Dry Eye

NCT05598242

Dry Eye Syndromes Sjogren Syndrome With Keratoconjunctivitis

COMPLETED PHASE3

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

NCT03431272

Contact Lens Dry Eye

WITHDRAWN PHASE4

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964

Dry Eye

TERMINATED NA

Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease

NCT03502447

Dry Eye Syndromes

TERMINATED NA

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518

Dry Eye

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eyes Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Treatment group to receive study drops (RegenerEyes) twice daily for 12 weeks

Group Type EXPERIMENTAL

RegenerEyes

Intervention Type BIOLOGICAL

Biologic eye drop

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RegenerEyes

Biologic eye drop

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (18 years or older)
* Presence of dry eye disease as defined as:

1. Ocular Suface Disease Index (OSDI) score \>13 AND EITHER i: Non-contact tear break-up time (NITBUT) \< 10 seconds OR ii: Ocular Surface Staining (OSS) score \> 1 in either eye

Exclusion Criteria

1. Systemic diseases or comorbidities that may cause severe or secondary dry eye:

1. Previous diagnosis of lymphoma, hepatitis C, HIV/AIDS, sarcoidosis, or amyloidosis that involves lacrimal glands
2. Previous diagnosis of graft versus host disease (e.g., after bone marrow transplantation treatment for cancer) or cicatrizing conjunctivitis (e.g., Steven Johnson Syndrome, mucous membrane pemphigoid, trachoma)
3. Anatomical or neurological lid closure problems (e.g., Bell's palsy, cicatricial ectropion, Alzheimer's disease, Parkinson's disease) 4
4. Any history of chemotherapy, head or neck radiation treatment, or radioactive iodine treatment within 1 year prior to enrollment
5. High dose oral or systemic steroids (equivalent to or greater than 5 mg prednisone) or immunosuppressive medication within 30 days prior to enrollment. Patients who are on stable dosing are eligible.
6. Frequent or recent change in systemic medication regimen (e.g., diuretics, beta blockers, immunosuppressive medications, antidepressants that are known to interfere with dry eye) within 3 months prior to enrollment that may influence the ocular surface.
2. Other ocular surface diseases or surgical history that may cause severe or secondary dry eye:

1. History of corneal dystrophy that in the opinion of the investigator is significantly affecting the ocular surface (e.g., significant anterior basement membrane dystrophy, Fuch's dystrophy with significant corneal edema and bullae, neurotrophic keratoconjunctivitis or corneal/conjunctival scarring including herpes simplex virus \[HSV\] or varicella zoster virus \[VZV\] keratitis)
2. Any history of surgery for glaucoma (e.g., trabeculectomy, tube shunt)
3. Corneal refractive surgery (e.g., laser in-situ keratomileusis \[LASIK\], photorefractive keratectomy \[PRK\], Intacs) within 6 months prior to enrollment
4. Cataract, eyelid surgery, or retinal surgery (in operating room) within 6 months prior to enrollment
3. Use of treatments that may interfere with the ocular surface and/or treatment efficacy:

1. Any in-office dry eye procedures (e.g., Intense Pulsed Light \[IPL\], LipiFlow®, nasolacrimal duct probing) within 30 days prior to enrollment
2. Use of anti-glaucoma drops, topical antihistamines drops, or topical steroid drops within 7 days prior to enrollment
3. Use of contact lenses. Patients willing to discontinue usage for 48 hours prior to each study visit will be eligible.
4. Use of scleral lens, such as the prosthetic replacement of the ocular surface ecosystem (PROSE) lens
5. Current use of topical lifitegrast (Xiidra®), topical cyclosporine (Restasis®), topical tacrolimus, or topical pimecrolimus. Patients willing to discontinue their due to insufficient benefit will be eligible.

1. Current smoker (within 1 year prior to enrollment).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes